Skip to main content
GutCited

Bifidobacterium longum के लिए Irritable Bowel Syndrome (IBS)

B

RCTs demonstrate significant reduction in IBS composite symptom score versus placebo. Particular benefit for bloating and abdominal distension. Marketed as Alflorex/Align.

<\/script>\n
`; }, get iframeSnippet() { const domain = 'gutcited.com'; const params = 'ingredient\u003Dbifidobacterium\u002Dlongum\u0026condition\u003Dibs'; return ``; }, get activeSnippet() { return this.method === 'script' ? this.scriptSnippet : this.iframeSnippet; }, copySnippet() { navigator.clipboard.writeText(this.activeSnippet).then(() => { this.copied = true; setTimeout(() => { this.copied = false; }, 2000); }); } }" @keydown.escape.window="open = false" @click.outside="open = false">

Embed This Widget

Style



      
      
    

Widget powered by . Free, no account required.

B

निष्कर्ष

RCTs demonstrate significant reduction in IBS composite symptom score versus placebo. Particular benefit for bloating and abdominal distension. Marketed as Alflorex/Align.

Key Study Findings

Meta-Analysis n=3154
Comparative effectiveness and safety of probiotics with psychotropic potential in mental health benefits in irritable …
Dose: None बनाम: placebo Outcome: quality of life, depression, and anxiety in IBS … प्रभाव: SUCRA=89.7% (B. longum for QoL); SUCRA=95.6% (probiotic combo for depression) None

जनसंख्या: patients with irritable bowel syndrome

Meta-Analysis
Strain-Specific Systematic Review with Meta-Analysis of Probiotics Efficacy in the Treatment of Irritable Bowel Syndrome.
Dose: None बनाम: placebo Outcome: improvement in key IBS symptoms प्रभाव: None None

जनसंख्या: patients with IBS from 32 RCTs evaluating 10 probiotic strains

In Vitro n=35
A Probiotic Mixture of Lactobacillus rhamnosus LR 32, Bifidobacterium lactis BL 04, and Bifidobacterium longum …
Dose: 1e6 CFU/mL बनाम: IBS supernatants without probiotic Outcome: Caco-2 paracellular permeability प्रभाव: None <0.001

जनसंख्या: IBS patients (28) and asymptomatic controls (7)

Review
The Role and the Regulation of NLRP3 Inflammasome in Irritable Bowel Syndrome: A Narrative Review.
Dose: None बनाम: None Outcome: IBS symptom management via NLRP3 inhibition प्रभाव: None None

जनसंख्या: Patients with IBS (narrative review)

Controlled Clinical Trial n=51 12 weeks Open-label
Targeted probiotic therapy in irritable bowel syndrome: a clinical evaluation on Clostridium butyricum CBM588 and …
Dose: None बनाम: Pre-treatment baseline Outcome: IBS-SSS score reduction प्रभाव: None None

जनसंख्या: IBS-D and IBS-C patients

Observational Study n=37 8 weeks Open-label
An 8-Week Course of Bifidobacterium longum 35624® Is Associated with a Reduction in the Symptoms …
Dose: None बनाम: None Outcome: Total IBS symptom score (TISS) प्रभाव: 43.4% TISS reduction; >60% >=30% responders None

जनसंख्या: Adults with IBS (Rome IV criteria)

Key Statistics

4

अध्ययन

600

प्रतिभागी

Positive

B

ग्रेड

Referenced Papers

Terapevticheskii arkhiv 2023 3 उद्धरण
The Cochrane database … 2020 14 उद्धरण
Current medical research … 2017 86 उद्धरण
Journal of gastroenterology … 2017 32 उद्धरण
Acta bio-medica : … 2006 41 उद्धरण

Dosage & Usage

mg = milligrams · mcg = micrograms (1,000× smaller) · IU = International Units

सामान्य रूप से उपयोग की जाने वाली खुराकें

general:
1-10 billion CFU/day
ibssupport:
1 billion CFU/day (35624 strain, marketed as Alflorex/Align)

अधिकतम सीमा: Well-tolerated up to 10 billion CFU/day in clinical trials

अनुसंधान में अध्ययन की गई खुराकें

खुराक अवधि प्रभाव N
None -- Positive 3154
None -- Positive --
1e6 CFU/mL -- Positive 35
None -- Positive --
None 12 weeks Positive 51
None 8 weeks Positive 37
1x10^10 CFU daily 6 weeks Positive 35
2 g 4 weeks Mixed --

सेवन का सर्वोत्तम समय: On an empty stomach or before meals

Safety & Side Effects

रिपोर्ट किए गए दुष्प्रभाव

  • Mild gas and bloating during initial use
  • Occasional abdominal discomfort
  • Rare loose stools
  • Very rare: bacteremia in immunocompromised individuals

ज्ञात अंतःक्रियाएँ

  • Antibiotics (may reduce probiotic viability; space dosing 2 hours apart)
  • Immunosuppressants (use with caution in immunocompromised patients)

सहनीय अधिकतम सेवन: Well-tolerated up to 10 billion CFU/day in clinical trials

कोई भी सप्लीमेंट शुरू करने से पहले हमेशा अपने स्वास्थ्य सेवा प्रदाता से परामर्श करें।

Frequently Asked Questions

Does Bifidobacterium longum help with Irritable Bowel Syndrome (IBS)?
Based on 4 studies with 600 participants, there is moderate evidence from clinical studies that Bifidobacterium longum may support Irritable Bowel Syndrome (IBS) management. Our evidence grade is B (Good Evidence).
How much Bifidobacterium longum should I take for Irritable Bowel Syndrome (IBS)?
Studies have used various dosages. A commonly studied range is 1-10 billion CFU/day. Always consult your healthcare provider before starting any supplement regimen.
Are there side effects of Bifidobacterium longum?
Reported side effects may include Mild gas and bloating during initial use, Occasional abdominal discomfort, Rare loose stools, Very rare: bacteremia in immunocompromised individuals. Most side effects are mild and dose-dependent. Consult your doctor if you experience any adverse reactions.
How strong is the evidence for Bifidobacterium longum and Irritable Bowel Syndrome (IBS)?
We rate the evidence as Grade B (Good Evidence). This rating is based on 4 peer-reviewed studies with 600 total participants. The overall direction of effect is positive.

Related Evidence

FDA अस्वीकरण: इन कथनों का Food and Drug Administration द्वारा मूल्यांकन नहीं किया गया है। इस वेबसाइट पर उत्पादों और जानकारी का उद्देश्य किसी बीमारी का निदान, उपचार, इलाज या रोकथाम नहीं है। प्रस्तुत साक्ष्य ग्रेड प्रकाशित पीयर-रिव्यूड अनुसंधान के हमारे विश्लेषण पर आधारित हैं और चिकित्सा सलाह नहीं हैं। कोई भी सप्लीमेंट शुरू करने से पहले हमेशा अपने स्वास्थ्य सेवा प्रदाता से परामर्श करें।